Table 1 Baseline characteristics of patients with lung cancer.

From: Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer

Characteristic

Total (n = 422)

Category 1 (n = 60)

Category 2 (n = 69)

Category 3 (n = 283)

Unknown (n = 10)

Age, years

70 (36–86)

71 (52–82)

71 (47–85)

69 (36–86)

72 (62–78)

Sex

 Female

48 (11.4)

8 (13.3)

9 (13.0)

29 (10.2)

2 (20.0)

 Male

374 (88.6)

52 (86.7)

60 (87.0)

254 (89.8)

8 (80.0)

Smoking

 Never smoker

62 (14.7)

7 (11.7)

10 (14.5)

45 (15.9)

0 (0.0)

 Current smoker

153 (36.3)

15 (25.0)

27 (39.1)

105 (37.1)

6 (60.0)

 Ex-smoker

207 (49.0)

38 (63.3)

32 (46.4)

133 (47.0)

4 (40.0)

Comorbidity

 ILD

44 (10.4)

5 (8.3)

25 (36.2)

14 (4.9)

0 (0.0)

  IPF

34 (77.3)

2 (40.0)

22 (88.0)

10 (71.4)

–

  Non-IPF

10 (22.7)

3 (60.0)

3 (12.0)

4 (28.6)

–

 COPD

214 (50.7)

24 (40.0)

34 (49.3)

148 (52.3)

8 (80.0)

ECOG PS score

 0

15 (3.5)

1 (1.7)

0 (0.0)

13 (4.6)

1 (10.0)

 1

298 (70.6)

34 (56.7)

45 (65.2)

212 (74.9)

7 (70.0)

 2

97 (23.0)

17 (28.3)

22 (31.9)

56 (19.8)

2 (20.0)

 3

8 (1.9)

5 (8.3)

1 (1.4)

2 (0.7)

0 (0.0)

 4

4 (1.0)

3 (5.0)

1 (1.4)

0 (0.0)

0 (0.0)

Pulmonary function

 FEV1, L (n = 370)

2.03 (0.52–3.80)

2.04 (0.66–3.67)

2.05 (0.90–3.32)

2.03 (0.52–3.80)

1.87 (1.54–3.72)

 FEV1, % (n = 370)

71.1 (20.1–124.5)

73.1 (25.6–124.5)

73.7 (30.2–103.3)

70.7 (20.1–120.6)

68.7 (58.0–106.6)

 FVC, L (n = 370)

2.86 (1.11–6.24)

2.84 (1.41–4.95)

2.73 (1.11–5.81)

2.91 (1.26–6.24)

3.03 (2.06–4.16)

 FVC, % (n = 370)

71.4 (30.8–116.8)

72.9 (32.9–108.8)

70.2 (33.4–116.8)

71.2 (30.8–110.6)

77.2 (51.9–85.1)

 DLCO, % (n = 324)

66.6 (24.9–133.0)

66.5 (36.7–133.0)

60.5 (24.9–110.7)

67.8 (29.2–126.2)

66.9 (54.3–98.6)

Serum CEA, ng/mL (n = 373)

5.50 (0.88–11,450.37)

4.77 (0.93–78.67)

7.40 (1.13–801.20)

5.36 (0.88–11,450.37)

9.50 (1.75–2248.70)

Serum CRP, mg/dL (n = 317)

1.42 (0.02–52.57)

3.78 (0.02–34.26)

0.92 (0.02–52.57)

1.44 (0.03–31.37)

0.36 (0.07–6.64)

Serum PCT, ng/mL (n = 73)

0.20 (0.03–2.87)

0.18 (0.04–1.48)

0.23 (0.04–2.33)

0.20 (0.03–2.87)

0.22 (NA)*

Histology

 Adenocarcinoma

154 (36.5)

21 (35.0)

32 (46.4)

99 (35.0)

2 (20.0)

Squamous cell carcinoma

174 (41.2)

25 (41.7)

22 (31.9)

120 (42.4)

7 (70.0)

 NSCLC, NOS

17 (4.0)

3 (5.0)

2 (2.9)

12 (4.2)

0 (0.0)

 Small cell lung carcinoma

77 (18.2)

11 (18.3)

13 (18.8)

52 (18.4)

1 (10.0)

Stage (TNM 8th)

 Early (I-III, LD)

178 (42.2)

27 (45.0)

37 (53.6)

108 (38.2)

6 (60.0)

 Advanced (IV, ED)

244 (57.8)

33 (55.0)

32 (46.4)

175 (61.8)

4 (40.0)

Driver mutations

 EGFR (tested, n = 191)

34/191 (17.8)

10/28 (35.7)

9/35 (25.7)

15/126 (11.9)

0/2 (0.0)

 ALK (tested, n = 186)

14/186 (7.5)

1/28 (3.6)

3/31 (9.7)

10/125 (8.0)

0/2 (0.0)

 ROS1 (tested, n = 166)

2/166 (1.2)

0/23 (0.0)

1/27 (3.7)

1/114 (0.9)

0/2 (0.0)

PD-L1 IHC, SP263 (tested)

(n = 312)

(n = 41)

(n = 49)

(n = 214)

(n = 8)

 TPS < 1%

120 (38.6)

15 (36.6)

26 (53.1)

74 (34.6)

5 (62.5)

 TPS ≥ 1%, < 50%

90 (28.8)

13 (31.7)

9 (18.3)

66 (30.8)

2 (25.0)

 TPS ≥ 50%

102 (32.6)

13 (31.7)

14 (28.6)

74 (34.6)

1 (12.5)

PD-L1 IHC, 22C3 (tested)

(n = 157)

(n = 24)

(n = 31)

(n = 99)

(n = 3)

 TPS < 1%

39 (24.8)

6 (25.0)

8 (25.8)

24 (24.2)

1 (33.3)

 TPS ≥ 1%, < 50%

56 (35.7)

5 (20.8)

11 (35.5)

39 (39.4)

1 (33.3)

 TPS ≥ 50%

62 (39.5)

13 (54.2)

12 (38.7)

36 (36.4)

1 (33.3)

Initial therapy of lung cancer

 Operation

59 (14.0)

11 (18.3)

10 (14.5)

37 (13.1)

1 (10.0)

 CCRT

162 (38.4)

23 (38.3)

29 (42.0)

107 (37.8)

3 (30.0)

 Systemic chemotherapy

180 (42.6)

22 (36.7)

22 (31.9)

132 (46.6)

4 (40.0)

 SBRT or RT alone

12 (2.8)

2 (3.3)

6 (8.7)

4 (1.4)

0 (0.0)

 Palliative treatment

3 (0.7)

0 (0.0)

1 (1.4)

2 (0.7)

0 (0.0)

 Supportive care

6 (1.4)

2 (3.3)

1 (1.4)

1 (0.4)

2 (20.0)

Immune-related adverse events (investigated, n = 270)

53/270 (19.6)

8/19 (42.1)

9/15 (60.0)

36/236 (15.3)

0/0 (0.0)

 ILD

24 (45.2)

5 (62.5)

8 (88.9)

11 (30.6)

–

 Non-ILD

29 (54.8)

3 (37.5)

1 (11.1)

25 (69.4)

–

ILD type

195 (46.2)

38 (63.3)

61 (88.4)

96 (33.9)

0 (0.0)

 DILD

51 (26.2)

19 (50.0)

19 (31.2)

13 (13.6)

–

 RP

119 (61.0)

18 (47.4)

26 (42.6)

75 (78.1)

–

 AE-ILD

25 (12.8)

1 (2.6)

16 (26.2)

8 (8.3)

–

Survival

 Live

244 (57.8)

23 (38.3)

41 (59.4)

175 (61.8)

5 (50.0)

 Death

73 (17.3)

18 (30.0)

13 (18.8)

42 (14.8)

0 (0.0)

 Lost follow-up or hopeless discharge

105 (24.9)

19 (31.7)

15 (21.7)

66 (23.3)

5 (50.0)

  1. Values are presented as medians (ranges) or numbers (%).
  2. ILD Interstitial lung disease, IPF Idiopathic pulmonary fibrosis, COPD Chronic obstructive pulmonary disease, ECOG Eastern Cooperative Oncology Group, PS Performance status, FEV1 Forced expiratory volume within 1 s, FVC Forced vital capacity, DLCO Diffusing capacity of lungs for carbon monoxide, CEA Carcinoembryonic antigen, CRP C-reactive protein, PCT Procalcitonin, NA Not available, NSCLC Non-small cell lung carcinoma, NOS Not otherwise specified, LD Limited disease (for small cell lung cancer), ED Extensive disease (for small cell lung cancer), EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, ROS1 ROS proto-oncogene 1, PD-L1 Programmed death-ligand 1, IHC Immunohistochemistry, TPS Tumor proportion score, CCRT Concurrent chemoradiation therapy, SBRT Stereotactic body radiation therapy, RT Radiation therapy, DILD Drug-induced ILD, RP Radiation-induced pneumonitis, AE-ILD Acute exacerbation of underlying ILD.
  3. *Only case.
Back to article page